Ars Pharmaceuticals Inc (SPRY)
13.90 x 15 14.40 x 5
Post-market by (Cboe BZX)
14.05 +0.81 (+6.12%) 04/11/25 [NASDAQ]
13.90 x 15 14.40 x 5
Post-market 14.05 unch (unch) 16:29 ET
for Fri, Apr 11th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | 7,998 | -54,365 | -34,682 | -20,243 | -32,947 |
Depreciation Amortization | -7,175 | -6,775 | 319 | 213 | 668 |
Accounts receivable | -8,175 | N/A | N/A | N/A | N/A |
Other Working Capital | -1,809 | -7,361 | -12,754 | -356 | -2,630 |
Other Operating Activity | 22,709 | 9,235 | 7,039 | 2,825 | 3,713 |
Operating Cash Flow | $13,548 | $-59,266 | $-40,078 | $-17,561 | $-31,196 |
Cash Flows From Investing Activities | |||||
Change In Deposits | -98,038 | -87,005 | N/A | N/A | N/A |
PPE Investments | -563 | -175 | -199 | -55 | -917 |
Purchase Sale Intangibles | -7,500 | N/A | N/A | N/A | N/A |
Other Investing Activity | -7,500 | 0 | 0 | 0 | 0 |
Investing Cash Flow | $-106,101 | $-87,180 | $-199 | $-55 | $-917 |
Cash Flows From Financing Activities | |||||
Debt Issued | 69,383 | N/A | N/A | N/A | N/A |
Common Stock Issued | 3,016 | 6,899 | 570 | 169 | 258,461 |
Other Financing Activity | 0 | 0 | 190,162 | 52,989 | 150,045 |
Financing Cash Flow | $72,399 | $6,899 | $190,732 | $53,158 | $408,506 |
Beginning Cash Position | 70,971 | 210,518 | 60,063 | 24,521 | 10,526 |
End Cash Position | 50,817 | 70,971 | 210,518 | 60,063 | 386,919 |
Net Cash Flow | $-20,154 | $-139,547 | $150,455 | $35,542 | $376,393 |
Free Cash Flow | |||||
Operating Cash Flow | 13,548 | -59,266 | -40,078 | -17,561 | -31,196 |
Capital Expenditure | -563 | -175 | -199 | -55 | -917 |
Free Cash Flow | 12,985 | -59,441 | -40,277 | -17,616 | -32,113 |